two weeks again, at least since Monday Aug 23:
Speaking of driving my Datsun, did you know that they recently made a Federal Speed Limit law, setting a maximum speed of 55 MPH thoughout the US? Apparently it was very unpopular and it was changed to allow speeds up to 65 MPH. I had never heard of such a thing.
Alan, why do you continue to make yourself a laughingstock by spewing about non-existent JFMs, when every smart, sane reader of this board knows that any pre-ex-date bounce comes from the irrefutable fact of short covering to avoid paying the dividend.
There never, ever were any such mythical beings as JFMs, even back in the 1980s when Japanese insurance companies briefly got preferential tax treatment on dividends, before the Nikkei crashed.
There was good news at the time but it had nothing to do with Aricept. It had to do with the fact that the dividend-capture season was imminent. THAT is why the stock started surging higher on July 26. At that time we were within the three to seven session period before ex-dividend date which is when you nearly always see the rallies.
Only a crazy person like you would fail to notice & recall that PFE in stubborn fact did start out-performing the S&P after that news hit.
Of course, it stopped doing so a month later, another "actual fact" which you ignore at your peril.
It's virtually no news at all when the drug only provided $432M in revenues to begin with and then exclusivity is being lost within just a few months.
Anybody that would be swayed by such minor stuff has to be crazy.
Clearly, you don't understand market psychology, or anything else about investing or PFE, as all here know.
Any good news, even if relatively small, is enough to cause a pop on short covering, when PFE has for so long suffered from nothing but bad news.
That's among the most small potatoes of small potatoes news. As if a higher approved dosage for an expiring drug is going to move the needle at all.
The patent for domestic Aricept expires the end of this year and Pfizer doesn't get that much from domestic sales anyhow - it's the international sales that they have the major rights to.
Pfizer's portion of domestic Aricept revenues only came to $432M in 2009. And of course that's headed much lower starting in 2011 with generic competition. The higher approved dosage means almost nothing.